Glaxo Advair "Approvable" At FDA; Flovent Tops $1 Bil. In 1999
Executive Summary
Glaxo Wellcome will respond to an FDA "approvable" letter for the asthma product Advair Diskus by Feb. 18, Chairman Richard Sykes indicated during a Feb. 16 analysts conference.
You may also be interested in...
Glaxo's Advair Combo Gets Broad Asthma Indication From FDA
Glaxo Wellcome's Advair Diskus will carry a broad indication for asthma patients requiring combination beta agonist/corticosteroid therapy.
Glaxo's Advair Combo Gets Broad Asthma Indication From FDA
Glaxo Wellcome's Advair Diskus will carry a broad indication for asthma patients requiring combination beta agonist/corticosteroid therapy.
Glaxo Diabetes Drug Will Face SB's Avandia; Anti-Herpetic Divestment Likely
Glaxo Wellcome intends to compete in the diabetes market with SmithKline Beecham's Avandia, Glaxo Chairman Richard Sykes indicated at an analysts earnings conference Feb. 16.